How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

211 results for

Ciclopirox

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

21. Nail penetration and predicted mycological efficacy of an innovative hydrosoluble ciclopirox nail lacquer vs. a standard amorolfine lacquer in healthy subjects. (PubMed)

Nail penetration and predicted mycological efficacy of an innovative hydrosoluble ciclopirox nail lacquer vs. a standard amorolfine lacquer in healthy subjects. In a previous study a new hydrosoluble nail lacquer (P-3051) containing 8% ciclopirox (CPX) showed higher nail penetration compared to a water-insoluble 5% amorolfine (MRF) lacquer. To our knowledge, in vivo human data on a similar topic are not available.To compare fingernail penetration of P-3051 with that of MRF reference in humans

Full Text available with Trip Pro

2013 Journal of the European Academy of Dermatology and Venereology : JEADV

22. Impact of the antiproliferative agent ciclopirox olamine treatment on stem cells proteome (PubMed)

Impact of the antiproliferative agent ciclopirox olamine treatment on stem cells proteome To investigate the proteome changes of stem cells due to ciclopirox olamine (CPX) treatment compared to control and retinoic acid treated cells.Stem cells (SCs) are cells, which have the ability to continuously divide and differentiate into various other kinds of cells. Murine embryonic stem cells (ESCs) and multipotent adult germline stem cells (maGSCs) were treated with CPX, which has been shown to have

Full Text available with Trip Pro

2013 World journal of stem cells

23. A Multicenter, Randomized, Open-Label, Controlled Study Comparing the Efficacy, Safety and Cost-Effectiveness of a Sequential Therapy with RV4104A Ointment, Ciclopiroxolamine Cream and Ciclopirox Film-Forming Solution with Amorolfine Nail Lacquer Alone in

A Multicenter, Randomized, Open-Label, Controlled Study Comparing the Efficacy, Safety and Cost-Effectiveness of a Sequential Therapy with RV4104A Ointment, Ciclopiroxolamine Cream and Ciclopirox Film-Forming Solution with Amorolfine Nail Lacquer Alone in The efficacy of topical antifungals is controversial.To compare the efficacy and safety of a sequential(SEQ) treatment with chemical nail avulsion and topical antifungals to amorolfine nail lacquer in dermatophytic onychomycosis.This (...) was a randomized,parallel-group, controlled study comparing a 36-week SEQ treatment with chemical nail avulsion with RV4104A ointment(class I medical device containing 40% urea) followed by ciclopirox cream for 8 weeks and ciclopirox nail lacquer for 25 weeks (SEQ group) to amorolfine nail lacquer for 36 weeks (AMO group). Patients had to have a big toenail onychomycosis,sparing the matrix. The primary efficacy criterion was complete cure at week 48. A cost-effectiveness analysis was performed.A total of 142

2013 Dermatology (Basel, Switzerland)

24. Safety Study of Ciclopirox Olamine Cream for Dermatomycoses in Children

Safety Study of Ciclopirox Olamine Cream for Dermatomycoses in Children Safety Study of Ciclopirox Olamine Cream for Dermatomycoses in Children - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Safety Study (...) of Ciclopirox Olamine Cream for Dermatomycoses in Children The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01646580 Recruitment Status : Terminated (Low recruitment rate. with the final sample primary endpoint could be assessed.) First Posted : July 20, 2012 Last Update Posted : July 20, 2012 Sponsor: Ferrer

2012 Clinical Trials

25. Ciclopirox

Ciclopirox Ciclopirox Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Ciclopirox Ciclopirox Aka: Ciclopirox , Loprox , Penlac From (...) Related Chapters II. Indications Dermatophyte Infection ( ) III. Preparations Cutaneous dermatophytes: Ciclopirox olamine 1% (Loprox) : Ciclopirox 8% lacquer (Penlac) IV. Mechanism: Broad-spectrum activity for dermatophytes and yeast Some antibacterial activity in vitro V. Efficacy (Loprox) More effective than OTC ( ) (Penlac) NOT recommended Requires 48 week application Minimally better than for cure rates Partial clearance rates are also poor Images: Related links to external sites (from Bing

2015 FP Notebook

26. Comparative clinical evaluation of efficacy and safety of a formulation containing ciclopirox 8% in the form of a therapeutic nail lacquer in two different posologies for the treatment of onychomycosis of the toes. (PubMed)

Comparative clinical evaluation of efficacy and safety of a formulation containing ciclopirox 8% in the form of a therapeutic nail lacquer in two different posologies for the treatment of onychomycosis of the toes. The use of topical antifungal agents in the treatment of onychomycosis is of great value in clinical practice as there are different limitations regarding the use of systemic treatment.To evaluate the efficacy and safety of a nail lacquer formulation containing ciclopirox 8% in two (...) of treatment resistance by T. mentagrophytes infection in both groups, without any predilection for sex, age, proportion of the nail affected at the beginning of the study, duration of the clinical disease and quantity of nails affected per person. Both groups had significant levels of mycological cure, clinical response and therapeutic success and there was no statistically significant difference between groups I and II (p >0.05).The nail lacquer containing ciclopirox 8% was equally effective at a weekly

2012 Anais brasileiros de dermatologia

27. Ciclopirox: a new topical pyrodonium antimycotic agent. A double-blind study in superficial dermatomycoses. (PubMed)

Ciclopirox: a new topical pyrodonium antimycotic agent. A double-blind study in superficial dermatomycoses. One percent Ciclopirox solution, a new topical antimycotic agent, was used in a double-blind controlled trial in 105 dermatomycosis patients. Twelve of the patients were lost to follow-up. Of the remaining ninety-three patients, forty-four were treated with the active drug, forty-nine with a placebo. The cure rate amongst those using ciclopirox was significantly superior

1976 The British journal of dermatology

28. A randomized, double-blind study comparing the efficacy of selenium sulfide shampoo 1% and ciclopirox shampoo 1% as adjunctive treatments for tinea capitis in children. (PubMed)

A randomized, double-blind study comparing the efficacy of selenium sulfide shampoo 1% and ciclopirox shampoo 1% as adjunctive treatments for tinea capitis in children. Our objective was to compare the efficacy of selenium sulfide shampoo 1% and ciclopirox shampoo 1% as adjunctive treatments for tinea capitis in children. Forty children aged 1-11 years with clinically diagnosed tinea capitis were randomized to receive selenium sulfide shampoo 1% or ciclopirox shampoo 1% twice a week as adjuncts (...) to an 8-week course of ultramicronized griseofulvin dosed at 10-12 mg/kg/day. At weeks 2, 4, and 8, subjects returned to the clinic for evaluation and scalp cultures. Subjects then returned for follow-up visits 4 weeks after completing treatment. Overall, by 8 weeks, 30 of 33 (90.9%) treated children demonstrated mycological cure. Selenium sulfide shampoo 1% and ciclopirox shampoo 1% were equally effective as adjunctive treatments for tinea capitis in children in our study.© 2010 Wiley Periodicals

2010 Pediatric dermatology

29. Overview of dermatitis

treatments when seborrhoeic dermatitis is confined to the scalp. Shuster S, Meynadier J, Kerl H, et al. Treatment and prophylaxis of seborrheic dermatitis of the scalp with antipityrosporal 1% ciclopirox shampoo. Arch Dermatol. 2005 Jan;141(1):47-52. https://jamanetwork.com/journals/jamadermatology/fullarticle/392182 http://www.ncbi.nlm.nih.gov/pubmed/15655141?tool=bestpractice.com Cradle cap in infants can usually be managed using emollients such as topical olive oil. Systemic antifungals should

2018 BMJ Best Practice

30. Overview of dermatitis

treatments when seborrhoeic dermatitis is confined to the scalp. Shuster S, Meynadier J, Kerl H, et al. Treatment and prophylaxis of seborrheic dermatitis of the scalp with antipityrosporal 1% ciclopirox shampoo. Arch Dermatol. 2005 Jan;141(1):47-52. https://jamanetwork.com/journals/jamadermatology/fullarticle/392182 http://www.ncbi.nlm.nih.gov/pubmed/15655141?tool=bestpractice.com Cradle cap in infants can usually be managed using emollients such as topical olive oil. Systemic antifungals should

2018 BMJ Best Practice

31. Putting the FUN in Fungi: Toenail onychomycosis treatments

-induced liver injury: ~1 in 50,000-120,000 prescriptions. 14 • Medication Costs: 15 o Oral (12 weeks): ? Terbinafine: ~$90 ? Itraconazole: ~$850 o Topical (48 weeks): 2 bottles per treatment. ? Ciclopirox: ~$150 ? Efinaconazole: ~$250 • Terbinafine treatment without confirmatory testing is likely most cost-effective approach. 16 • Although not always statistically different, some RCTs found clinically relevant improvements with 4-6-month oral treatment regimens compared to 3 months. 3,17 Authors

2019 Tools for Practice

32. Onychomycosis

Not evaluated for more extensive OM (when > 50% of the nail is involved) Safety in pediatrics (less than 18 years of age), pregnant and lactating women has not been evaluated Apply once daily to affected nail(s) for 48 weeks No debridement required Available in a 6 ml container which provides 80 applications Ciclopirox 8% nail lacquer (not appropriate for pharmacist prescribing) Ciclopirox is not approved for pharmacist prescribing due to limited effectiveness and cost Limited efficacy for toenail

2018 medSask

33. Neodymium-doped yttrium aluminium garnet laser treatment for onychomycosis

(milliseconds), short-pulsed (microseconds), and Qswitched (nanoseconds). Patient Population: Laser therapy is indicated for patients with toenail or fingernail onychomycosis. Clinical Alternatives: Onychomycosis may be treated with oral (e.g., terbinafine, itraconazole, fluconazole, posaconazole, griseofulvin) or topical (e.g., ciclopirox olamine, efinaconazole, amorolfine, bifonazole, tioconazole, tavaborate) antifungal agents or nonpharmacologic treatments (e.g., laser treatment, photodynamic therapy

2017 Health Technology Assessment (HTA) Database.

34. Efficacy, Safety and Cost-effectiveness of a Sequential Therapy With RV4104A Ointment, Ciclopiroxolamine Cream and Ciclopirox Film-forming Solution Compared With Amorolfine Nail Lacquer in Dermatophytic Onychomycosis

Efficacy, Safety and Cost-effectiveness of a Sequential Therapy With RV4104A Ointment, Ciclopiroxolamine Cream and Ciclopirox Film-forming Solution Compared With Amorolfine Nail Lacquer in Dermatophytic Onychomycosis Efficacy, Safety and Cost-effectiveness of a Sequential Therapy With RV4104A Ointment, Ciclopiroxolamine Cream and Ciclopirox Film-forming Solution Compared With Amorolfine Nail Lacquer in Dermatophytic Onychomycosis - Full Text View - ClinicalTrials.gov Hide glossary Glossary (...) Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Efficacy, Safety and Cost-effectiveness of a Sequential Therapy With RV4104A Ointment, Ciclopiroxolamine Cream and Ciclopirox Film-forming Solution Compared With Amorolfine Nail Lacquer in Dermatophytic Onychomycosis (ONICO

2009 Clinical Trials

35. An innovative water-soluble biopolymer improves efficacy of ciclopirox nail lacquer in the management of onychomycosis. (PubMed)

An innovative water-soluble biopolymer improves efficacy of ciclopirox nail lacquer in the management of onychomycosis. A new 8% ciclopirox-medicated nail lacquer (P-3051), based on a new technology, revealed superior properties in terms of affinity to keratin, nail permeation, and ease of use.This study aims to assess the efficacy and safety of P-3051 vs. the market 8% ciclopirox nail lacquer.This is a multicentre, randomized, three-arm, placebo-controlled, parallel groups, evaluator-blinded (...) ), and those who achieved the endpoint 'decrease of diseased nail' were 40% higher (P < 0.05).Ciclopirox 8% hydrolacquer is more active than reference ciclopirox nail lacquer in the treatment of onychomycosis.

2009 Journal of the European Academy of Dermatology and Venereology : JEADV

36. Study Evaluating the Tolerance and Biologic Activity of Oral Ciclopirox Olamine in Patients With Relapsed or Refractory Hematologic Malignancy

Study Evaluating the Tolerance and Biologic Activity of Oral Ciclopirox Olamine in Patients With Relapsed or Refractory Hematologic Malignancy Study Evaluating the Tolerance and Biologic Activity of Oral Ciclopirox Olamine in Patients With Relapsed or Refractory Hematologic Malignancy - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save (...) this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Study Evaluating the Tolerance and Biologic Activity of Oral Ciclopirox Olamine in Patients With Relapsed or Refractory Hematologic Malignancy The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details

2009 Clinical Trials

37. Inhibition of HIV-1 gene expression by Ciclopirox and Deferiprone, drugs that prevent hypusination of eukaryotic initiation factor 5A (PubMed)

Inhibition of HIV-1 gene expression by Ciclopirox and Deferiprone, drugs that prevent hypusination of eukaryotic initiation factor 5A Eukaryotic translation initiation factor eIF5A has been implicated in HIV-1 replication. This protein contains the apparently unique amino acid hypusine that is formed by the post-translational modification of a lysine residue catalyzed by deoxyhypusine synthase and deoxyhypusine hydroxylase (DOHH). DOHH activity is inhibited by two clinically used drugs (...) , the topical fungicide ciclopirox and the systemic medicinal iron chelator deferiprone. Deferiprone has been reported to inhibit HIV-1 replication in tissue culture.Ciclopirox and deferiprone blocked HIV-1 replication in PBMCs. To examine the underlying mechanisms, we investigated the action of the drugs on eIF5A modification and HIV-1 gene expression in model systems. At early times after drug exposure, both drugs inhibited substrate binding to DOHH and prevented the formation of mature eIF5A. Viral gene

Full Text available with Trip Pro

2009 Retrovirology

38. Comparison of tumor related signaling pathways with known compounds to determine potential agents for lung adenocarcinoma (PubMed)

in the search for potential LUAD treatments, most importantly, the p53 signaling pathway. Some compounds, such as ciclopirox and AG-028671, may have potential roles for LUAD treatment but require further experimental verification.© 2018 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd.

Full Text available with Trip Pro

2018 Thoracic cancer

39. Patient-reported outcomes from two randomised studies comparing once-weekly application of amorolfine 5% nail lacquer to other methods of topical treatment in distal and lateral subungual onychomycosis. (PubMed)

% nail lacquer versus once-daily ciclopirox 8% nail lacquer (Study A) or once-daily urea 40% ointment/bifonazole 1% cream combination regimen (Study B). Study A: Subjects received amorolfine and ciclopirox on opposite feet for 12 weeks. Study B: Subjects received amorolfine and urea/bifonazole on opposite feet for 6-7 weeks. Assessments included subject adherence as per label, treatment preference and questionnaire. Study A: More subjects adhered to amorolfine (85%) than to ciclopirox (60%) (P = .025

Full Text available with Trip Pro

2018 Mycoses

40. Mutation in the Squalene epoxidase gene of <i>Trichophyton interdigitale</i> and <i>Trichophyton rubrum</i> associated with allylamine resistance. (PubMed)

, terbinafine, naftifine, amorolfine, ciclopirox olamine, griseofulvin, and luliconazole. The squalene epoxidase gene was evaluated for mutation (if any) in 15 T. interdigitale and 5 T. rubrum isolates exhibiting high MICs for terbinafine. A T1189C mutation was observed in four T. interdigitale and two T. rubrum isolates. This transition leads to the change of phenylalanine to leucine in the 397th position of the squalene epoxidase enzyme. In homology modeling the mutant residue was smaller than the wild

Full Text available with Trip Pro

2018 Antimicrobial Agents and Chemotherapy

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>